Rice Hall James & Associates, LLC Ligand Pharmaceuticals Inc Transaction History

Rice Hall James & Associates, LLC

  • $1.63 Billion
  • Q1 2024

A detailed history of Rice Hall James & Associates, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 279,784 shares of LGND stock, worth $23.6 Million. This represents 1.25% of its overall portfolio holdings.

Number of Shares
279,784
Previous 276,008 1.37%
Holding current value
$23.6 Million
Previous $19.7 Million 3.75%
% of portfolio
1.25%
Previous 1.19%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024
BUY
$68.64 - $89.2 $259,184 - $336,819
3,776 Added 1.37%
279,784 $20.5 Million
Q4 2023

Feb 08, 2024
SELL
$49.57 - $72.63 $344,660 - $504,996
-6,953 Reduced 2.46%
276,008 $19.7 Million
Q3 2023

Nov 02, 2023
SELL
$58.86 - $72.67 $305,954 - $377,738
-5,198 Reduced 1.8%
282,961 $17 Million
Q2 2023

Jul 24, 2023
SELL
$69.53 - $79.33 $12,932 - $14,755
-186 Reduced 0.06%
288,159 $20.8 Million
Q1 2023

May 11, 2023
BUY
$65.67 - $77.08 $178,031 - $208,963
2,711 Added 0.95%
288,345 $21.2 Million
Q4 2022

Jan 27, 2023
SELL
$61.72 - $96.74 $681,635 - $1.07 Million
-11,044 Reduced 3.72%
285,634 $0
Q3 2022

Nov 01, 2022
SELL
$0.01 - $107.56 $379 - $4.08 Million
-37,964 Reduced 11.34%
296,678 $25.5 Million
Q2 2022

Aug 08, 2022
SELL
$74.52 - $117.06 $769,568 - $1.21 Million
-10,327 Reduced 2.99%
334,642 $29.9 Million
Q1 2022

May 05, 2022
SELL
$94.99 - $151.56 $259,322 - $413,758
-2,730 Reduced 0.79%
344,969 $38.8 Million
Q4 2021

Feb 14, 2022
SELL
$127.69 - $165.85 $3.32 Million - $4.32 Million
-26,021 Reduced 6.96%
347,699 $53.7 Million
Q3 2021

Nov 09, 2021
SELL
$102.33 - $144.73 $512,263 - $724,518
-5,006 Reduced 1.32%
373,720 $52.1 Million
Q2 2021

Jul 29, 2021
SELL
$113.03 - $155.64 $5.8 Million - $7.99 Million
-51,330 Reduced 11.94%
378,726 $49.7 Million
Q1 2021

May 14, 2021
SELL
$99.52 - $215.83 $7.37 Million - $16 Million
-74,103 Reduced 14.7%
430,056 $65.6 Million
Q4 2020

Feb 16, 2021
BUY
$80.55 - $106.05 $9.48 Million - $12.5 Million
117,653 Added 30.44%
504,159 $50.1 Million
Q3 2020

Nov 16, 2020
BUY
$89.56 - $126.72 $4.9 Million - $6.94 Million
54,766 Added 16.51%
386,506 $36.8 Million
Q2 2020

Aug 14, 2020
SELL
$68.28 - $123.65 $453,106 - $820,541
-6,636 Reduced 1.96%
331,740 $37.1 Million
Q1 2020

May 15, 2020
BUY
$63.37 - $107.88 $2.27 Million - $3.87 Million
35,873 Added 11.86%
338,376 $24.6 Million
Q4 2019

Jan 29, 2020
SELL
$96.94 - $113.59 $1.28 Million - $1.51 Million
-13,251 Reduced 4.2%
302,503 $31.5 Million
Q3 2019

Oct 30, 2019
SELL
$86.25 - $120.16 $559,848 - $779,958
-6,491 Reduced 2.01%
315,754 $31.4 Million
Q2 2019

Aug 01, 2019
SELL
$107.38 - $129.34 $2.14 Million - $2.57 Million
-19,896 Reduced 5.82%
322,245 $36.8 Million
Q1 2019

May 01, 2019
BUY
$105.93 - $142.47 $7.12 Million - $9.58 Million
67,224 Added 24.45%
342,141 $43 Million
Q4 2018

Feb 14, 2019
BUY
$128.36 - $272.13 $10.7 Million - $22.7 Million
83,586 Added 43.69%
274,917 $37.3 Million
Q3 2018

Oct 25, 2018
SELL
$211.18 - $274.49 $16 Million - $20.7 Million
-75,589 Reduced 28.32%
191,331 $52.5 Million
Q2 2018

Aug 02, 2018
SELL
$150.77 - $207.98 $5.69 Million - $7.86 Million
-37,772 Reduced 12.4%
266,920 $55.3 Million
Q1 2018

Apr 25, 2018
SELL
$138.63 - $182.62 $300,272 - $395,554
-2,166 Reduced 0.71%
304,692 $50.3 Million
Q4 2017

Jan 23, 2018
BUY
$128.36 - $147.04 $4.99 Million - $5.71 Million
38,844 Added 14.49%
306,858 $42 Million
Q3 2017

Oct 30, 2017
BUY
$120.91 - $137.94 $32.4 Million - $37 Million
268,014
268,014 $36.5 Million

Others Institutions Holding LGND

# of Institutions
234
Shares Held
16.5M
Call Options Held
77.9K
Put Options Held
25K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.42B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email